Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Ulcerative Colitis Guidance: 'Ideal' Vision Vs. Practical Interim Approach

Executive Summary

Agency favors assessments of signs/symptoms and endoscopy findings using well-defined and reliable patient- and clinician-reported outcomes instruments; since these don't exist, FDA will allow tweaking of existing assessment tools in the interim.

Advertisement

Related Content

Pfizer Eyes Xeljanz Expansion To Ulcerative Colitis
Past Trials Can Provide Score For Temporary Ulcerative Colitis Endpoint, FDA Told
FDA, Industry Seek Temporary Endpoint For Assessing Ulcerative Colitis Drugs
Pediatric IBD Studies Should Assess Disease Activity, Panel Says

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS118991

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel